Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4091117 | 1.00 | OGA (0.39) | OGAALDH1A1MAPTLMNAGAA | |
| Trifluoroacetic Acid SCHEMBL4093888 | 0.99 | OGA (0.40) | OGAALDH1A1MAPTLMNAGAA | |
| Trifluoroacetic Acid SCHEMBL4093894 | 0.99 | OGA (0.40) | OGAALDH1A1MAPTLMNAGAA | |
| SCHEMBL3641882 | 0.95 | OGA (0.42) | OGAHPGDMAPK10TERTDYRK3 | |
| SCHEMBL3641881 | 0.95 | OGA (0.42) | OGAHPGDMAPK10TERTDYRK3 | |
| SCHEMBL2985523 | 0.94 | OGA (0.43) | OGAALDH1A1HPGDMAPK10TERT | |
| SCHEMBL2985521 | 0.94 | OGA (0.43) | OGAALDH1A1HPGDMAPK10TERT | |
| Trifluoroacetic Acid SCHEMBL4102103 | 0.94 | OGA (0.39) | OGAALDH1A1MAPTLMNAGAA | |
| Trifluoroacetic Acid SCHEMBL4102095 | 0.94 | OGA (0.39) | OGAALDH1A1MAPTLMNAGAA | |
| Trifluoroacetic Acid SCHEMBL4095073 | 0.93 | WNT3A (0.40) | OGAALDH1A1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | OGA 1432/4885ALDH1A1 4089/4885MAPT 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.